Page last updated: 2024-11-04

rofecoxib and Hypokalemia

rofecoxib has been researched along with Hypokalemia in 1 studies

Hypokalemia: Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Gitelman's syndrome is manifested by hypokalemic alkalosis, hypomagnesemia, hypocalciuria, normotensive hyperreninemia and hyperaldosteronism."1.31Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. ( Farfel, Z; Gurevitz, O; Mayan, H, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mayan, H1
Gurevitz, O1
Farfel, Z1

Other Studies

1 other study available for rofecoxib and Hypokalemia

ArticleYear
Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome.
    Clinical nephrology, 2002, Volume: 58, Issue:1

    Topics: Adult; Alkalosis; Calcium; Cyclooxygenase Inhibitors; Humans; Hyperaldosteronism; Hypokalemia; Lacto

2002